 |
 |
 |
|
Intranasal Morphine Gluconate for Breakthrough Cancer PainDescription:Morphine is a well known opioid analgesic currently marketed in multiple dosage forms including those for injectable, oral and rectal administration. Nastech has developed a nasal dosage form of its patented morphine gluconate molecule, an enhanced delivery form of morphine. This formulation is designed to allow for patient-friendly self administration and provides for rapid absorption of the dose of morphine required to adequately treat breakthrough cancer pain. Development Status:Nastech reported positive results from a Phase II clinical trial of intranasal morphine gluconate in December 2002. Clinical Need:Breakthrough pain can occur in patients treated with long-acting opioid agents for chronic conditions such as cancer. There is only one agent currently approved for treating breakthrough cancer pain, a transmucosal oral fentanyl product. Intranasal morphine gluconate is being developed to have a more rapid onset of pain relief. Partnership Status:
Available for Licensing
|
|
| © 2006 NASTECH Legal Notice | |
|
|
